In Brief: Coram v. Caremark
Executive Summary
Coram v. Caremark: Coram Healthcare reaches settlement with Caremark in suit arising from Coram's acquisition of Caremark's home infusion business in 1995. Coram sued Caremark in September 1995; Caremark countersued a month later ("The Pink Sheet" Oct. 23, 1995, T&G-5). Caremark will forgive all promissory notes from Coram, totaling approximately $120 mil. Caremark will also pay $45 mil. in cash to Coram by Sept. 1. Coram will record a one-time pretax gain of approximately $165 mil. The parties will dismiss their lawsuits and counterclaims...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth